Skip to content

Author

E. Pruszyńska-Oszmałek

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial

Background: Time-restricted eating (TRE) appears to be a promising dietary strategy for women with polyendocrine metabolic ovarian syndrome (PMOS), with potential benefits for insulin resistance and metabolic health. Emerging evidence also suggests that TRE may be associated with changes in gut microbiota composition a...

J. Pieczyńska-Zając, S. Drzymała-Czyż, E. Pruszyńska-Oszmałek et al. · 0 citations
Open access Oct 2026

Interaction Analysis of VDR rs7975232 Polymorphism and the Triglyceride-Glucose Index in Relation to Metabolic Outcomes in Older Adults

Ageing is associated with increasing metabolic heterogeneity driven by interactions between adipose tissue dysfunction and altered glucose-lipid metabolism. The vitamin D receptor (VDR) rs7975232 polymorphism has been investigated in relation to metabolic traits; however, its relationship with glucose–lipid metabolic c...

Szymon Michniewicz, K. Chmielowiec, J. Chmielowiec et al. · 0 citations
Open access Aug 2026

LEAP2 Regulates Insulin Secretion from INS-1E Beta Cells and Rat Pancreatic Islets: An In Vitro Study

LEAP2 is an endogenous antagonist and inverse agonist of GHSR-1a, the receptor for acyl-ghrelin. Although LEAP2 is increasingly recognized as a regulator of appetite and glucose homeostasis, its direct effects on pancreatic endocrine cells remain incompletely understood. The present in vitro study evaluated whether LEA...

Oskar Sosinski, E. Pruszyńska-Oszmałek, M. Sassek et al. · 0 citations
Review Open access Sep 2026

Contemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy

Overall, treatment selection is increasingly determined by tumour type, stage, resectability and validated biomarkers, while several important questions concerning optimal sequencing, long-term outcomes and under-represented patient groups remain unresolved.

Dariusz Kowalczyk, J. Jaworek, Andrzej Ciborek et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.